

Title: First-in-human randomized trial to assess safety, tolerability, pharmacokinetics and pharmacodynamics of the KDM1A inhibitor vafidemstat

Short Title: First-in-Human of KDM1A inhibitor vafidemstat

Rosa María Antonijoan^{1,2}, Juan Manuel Ferrero-Cafiero¹, Jimena Coimbra¹, Montse Punes¹, Joan Martínez-Colomer¹, María Isabel Arévalo³, Cristina Mascaró³, Cesar Molinero³, Carlos Buesa³, Tamara Maes^{3,*}.

¹Centre d'Investigació del Medicament, Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau (IIB-Sant Pau), Barcelona, Spain.

²Pharmacology and Therapeutics Department. Universitat Autònoma de Barcelona (UAB), Bellaterra, Spain.

³Oryzon Genomics S.A. Cornellà de Llobregat, Barcelona, Spain.

*Corresponding author:

Tamara Maes

Address: Carrer Sant Ferran 74, 08940 Cornellà de Llobregat, Barcelona, Spain

Email: tmaes@oryzon.com (TM)

Telephone: +34 665602247

ORCID: 0000-0001-5104-6867

Online Resource 3

Supplemental Figures




Figure S1. Vafidemstat pharmacodynamics (PD).

No significant inhibition is detected of **a** MAO-B activity after single ascending doses (SAD). White bars: pre-dose; light blue bars: 12 h; dark blue bars: 72 h after the first dose. **b** MAO-B activity during and after multiple ascending doses (MAD) in healthy young subjects. White bars: pre-dose; light blue bars: 12 h; medium blue bars: 108 h; dark blue bars: 192 h after the first dose. Graphs represent mean and SEM values. Volunteers sampled at each dose: n = 6 except MAD 4 mg: n = 3. Samples that did not pass quality control were omitted. SAD: Single Ascending Dose, MAD: Multiple Ascending Dose, SEM: Standard Error of the Mean.